Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
BörsenkürzelAVR
Name des UnternehmensAnteris Technologies Global Corp
IPO-datumDec 13, 2024
CEOPaterson (Wayne G)
Anzahl der mitarbeiter136
WertpapierartOrdinary Share
GeschäftsjahresendeDec 13
Addresse860 Blue Gentian Road
StadtEAGAN
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl55121
Telefon16514930606
Websitehttps://anteristech.com/
BörsenkürzelAVR
IPO-datumDec 13, 2024
CEOPaterson (Wayne G)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten